Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1941 Dose-Response Study in Type 2 Diabetes
NCT00621868Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ipragliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Astellas Pharma. Primary endpoint: HbA1c level at 12 weeks. Started Mar 2008; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00621868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621868.